Login
Super Investors GSK plc
GP

GSK plc

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$497M
Positions
13
Quarter ended
September 30, 2026
Filed
November 05, 2026

Reported portfolio value by quarter (4 quarters reported)

$799M $497M
Q4 25 Q1 26 Q2 26 Q3 26

$799M in Q4 2025 → $497M now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
Crispr Therapeutics Ag 29.0% Trimmed 19% 2,608,419 $144M
Vir Biotechnology Inc 19.2% Unchanged 8,550,954 $95.6M
Wave Life Sciences Inc 13.6% New 18,245,691 $67.5M
Biontech Se 13.2% Trimmed 25% 668,526 $65.7M
Ideaya Biosciences Inc 10.3% Unchanged 1,333,333 $51.2M
Cytokinetics Inc 4.5% Unchanged 340,434 $22.4M
Lyell Immunopharma Inc 3.0% Unchanged 1,512,659 $14.8M
Spero Therapeutics Inc 2.2% Unchanged 9,190,606 $11.1M
Nkarta Inc 1.7% Unchanged 3,150,732 $8.25M
Fulcrum Therapeutics Inc 1.3% Unchanged 1,785,714 $6.61M
Bicycle Therapeutics PLC 1.1% Unchanged 1,529,561 $5.63M
Regenxbio Inc 0.4% Unchanged 271,456 $2.04M
Cvrx Inc 0.4% Unchanged 1,007,583 $1.76M

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 3 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 05, 2026

Company Action Shares changed Value of change % of portfolio
Wave Life Sciences Ltd Exited −18,245,691 −$106M —
Wave Life Sciences Inc New +18,245,691 +$67.5M 13.6%
Crispr Therapeutics Ag Trimmed −612,208 −$33.9M 29.0%
Biontech Se Trimmed −221,298 −$21.8M 13.2%

Q2 2026

quarter ended June 30, 2026 · filed August 13, 2026

No position changes this quarter.

Q1 2026

quarter ended March 31, 2026 · filed May 14, 2026

Company Action Shares changed Value of change % of portfolio
SH Senseonics Hldgs Inc Exited −10,856 −$59.9K —
Harvard Bioscience Inc Exited −11,151 −$7.46K —

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support